SG Americas Securities’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-30,710
| Closed | -$21K | – | 3747 |
|
|
2025
Q3 | $21K | Buy |
+30,710
| New | +$16.6K | ﹤0.01% | 3287 |
|
|
2024
Q2 | – | Sell |
-58,584
| Closed | -$39K | – | 3264 |
|
|
2024
Q1 | $39K | Sell |
58,584
-121,960
| -68% | -$88.5K | ﹤0.01% | 2803 |
|
|
2023
Q4 | $98K | Buy |
180,544
+92,002
| +104% | +$42.4K | ﹤0.01% | 2776 |
|
|
2023
Q3 | $53K | Buy |
88,542
+63,612
| +255% | +$68.1K | ﹤0.01% | 2927 |
|
|
2023
Q2 | $32K | Sell |
24,930
-49,226
| -66% | -$67.3K | ﹤0.01% | 2160 |
|
|
2023
Q1 | $131K | Buy |
74,156
+22,026
| +42% | +$62.9K | ﹤0.01% | 2733 |
|
|
2022
Q4 | $164K | Sell |
52,130
-22,143
| -30% | -$85.9K | ﹤0.01% | 2353 |
|
|
2022
Q3 | $364K | Sell |
74,273
-49,434
| -40% | -$254K | ﹤0.01% | 1826 |
|
|
2022
Q2 | $512K | Buy |
+123,707
| New | +$535K | 0.01% | 1939 |
|
|
2022
Q1 | – | Sell |
-38,283
| Closed | -$287K | – | 3374 |
|
|
2021
Q4 | $287K | Sell |
38,283
-629,498
| -94% | -$5.47M | ﹤0.01% | 2466 |
|
|
2021
Q3 | $6.02M | Buy |
667,781
+48,356
| +8% | +$478K | 0.03% | 459 |
|
|
2021
Q2 | $7.42M | Buy |
619,425
+525,952
| +563% | +$5.95M | 0.03% | 451 |
|
|
2021
Q1 | $1.17M | Buy |
93,473
+62,521
| +202% | +$842K | 0.01% | 1426 |
|
|
2020
Q4 | $483K | Sell |
30,952
-55,874
| -64% | -$655K | ﹤0.01% | 2009 |
|
|
2020
Q3 | $821K | Buy |
86,826
+69,639
| +405% | +$753K | 0.01% | 1309 |
|
|
2020
Q2 | $154K | Sell |
17,187
-150,633
| -90% | -$1.4M | ﹤0.01% | 3078 |
|
|
2020
Q1 | $1.07M | Buy |
+167,820
| New | +$1.25M | 0.01% | 1240 |
|
|
2019
Q4 | – | Sell |
-17,138
| Closed | -$155K | – | 3411 |
|
|
2019
Q3 | $155K | Sell |
17,138
-4,100
| -19% | -$46K | ﹤0.01% | 2492 |
|
|
2019
Q2 | $229K | Buy |
+21,238
| New | +$226K | ﹤0.01% | 2340 |
|
|
2018
Q3 | – | Sell |
-9,484
| Closed | -$135K | – | 3430 |
|
|
2018
Q2 | $135K | Sell |
9,484
-46
| -0.5% | -$764 | ﹤0.01% | 2885 |
|
|
2018
Q1 | $181K | Sell |
9,530
-34,914
| -79% | -$746K | ﹤0.01% | 2494 |
|
|
2017
Q4 | $729K | Sell |
44,444
-26,840
| -38% | -$399K | 0.01% | 1600 |
|
|
2017
Q3 | $1.07M | Buy |
71,284
+375
| +0.5% | +$4.15K | 0.01% | 1205 |
|
|
2017
Q2 | $624K | Buy |
70,909
+9,946
| +16% | +$63.8K | 0.01% | 1715 |
|
|
2017
Q1 | $317K | Sell |
60,963
-19,940
| -25% | -$80K | ﹤0.01% | 2138 |
|
|
2016
Q4 | $247K | Buy |
80,903
+62,320
| +335% | +$227K | ﹤0.01% | 2200 |
|
|
2016
Q3 | $86K | Buy |
+18,583
| New | +$94.5K | ﹤0.01% | 3108 |
|
|
2016
Q1 | – | Sell |
-27,617
| Closed | -$252K | – | 3220 |
|
|
2015
Q4 | $252K | Sell |
27,617
-17,768
| -39% | -$137K | ﹤0.01% | 1974 |
|
|
2015
Q3 | $256K | Buy |
+45,385
| New | +$374K | ﹤0.01% | 1309 |
|
|
2015
Q2 | – | Sell |
-7,389
| Closed | -$116K | – | 2802 |
|
|
2015
Q1 | $116K | Sell |
7,389
-1,865
| -20% | -$28.9K | ﹤0.01% | 2187 |
|
|
2014
Q4 | $141K | Buy |
+9,254
| New | +$112K | ﹤0.01% | 2693 |
|
|
2013
Q4 | – | Sell |
-15,726
| Closed | -$165K | – | 2966 |
|
|
2013
Q3 | $165K | Buy |
+15,726
| New | +$156K | ﹤0.01% | 2320 |
|
Other funds holding SGMO
WA
SG Americas Securities's SGMO Position: Q4 2025 in Review
SG Americas Securities sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2025, closing a stake of 30,710 shares — an estimated $21K sold.
SG Americas Securities first reported a position in SGMO in Q3 2013 and held it in 32 quarters. The position peaked at $7.42M in Q2 2021. 105 funds tracked by Wall St. Rank hold SGMO as of Q4 2025.
- SG Americas Securities reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2025 after selling out during the quarter.
- SG Americas Securities sold 30,710 SANGAMO THERAPEUTICS INC shares in Q4 2025, an estimated $21K.
- SG Americas Securities first reported a position in SANGAMO THERAPEUTICS INC in Q3 2013 and held it in 32 quarters.
- SG Americas Securities's SANGAMO THERAPEUTICS INC position peaked at $7.42M in Q2 2021.
- 105 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2025.
Based on SG Americas Securities's 13F filing for Q4 2025, filed 9 Jan 2026.